Peregrine Pharmaceuticals reported $9.12M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Agenus AGEN:US USD 22.46M 3.56M
Amgen AMGN:US USD 5.06B 20M
AstraZeneca AZN:LN USD 8.86B 3M
Biocryst Pharmaceuticals BCRX:US USD 72.21M 6.93M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Eli Lilly And LLY:US USD 5.36B 305M
GlaxoSmithKline GSK:LN GBP 5.44B 650M
Intrexon XON:US USD 15.14M 14.04M
Karyopharm Therapeutics KPTI:US USD 35.16M 3.58M
MacroGenics MGNX:US USD 38.59M 14.99M
Mannkind MNKD:US USD 15.36M 9.39M
Merk MRK:US USD 11.52B 1.08B
Novartis NOVN:VX USD 9.18B 151M
Peregrine Pharmaceuticals PPHM:US USD 9.12M 2.13M
Repligen RGEN:US USD 114.23M 7.15M
Roche Holding ROG:VX 22.73B 924M